Category Press Releases

Neurocrine

Neurocrine Biosciences Launches Phase 2 Trial of NBI-1065890 for Tardive Dyskinesia in Adults

Neurocrine Biosciences Launches Phase 2 Trial of NBI-1065890 for Tardive Dyskinesia in Adults Neurocrine Biosciences, Inc. today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with tardive dyskinesia (TD). NBI-1065890 is a next-generation,…

Read MoreNeurocrine Biosciences Launches Phase 2 Trial of NBI-1065890 for Tardive Dyskinesia in Adults
WuXi Biologics

WuXi Biologics, HanchorBio Partner on Next-Gen Fusion Proteins

WuXi Biologics and HanchorBio Forge Strategic Partnership to Advance Next-Gen Bi- and Multi-Functional Fusion Proteins WuXi Biologics, a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies…

Read MoreWuXi Biologics, HanchorBio Partner on Next-Gen Fusion Proteins

Trelegy Ellipta Gains Approval in China for Adults with Uncontrolled Asthma

Trelegy Ellipta Gains Approval in China for Adults with Uncontrolled Asthma GSK plc today announced that China’s National Medical Products Administration (NMPA) has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC/VI’) for the treatment of patients…

Read MoreTrelegy Ellipta Gains Approval in China for Adults with Uncontrolled Asthma
Lilly

Lilly’s Mirvetuximab Soravtansine Earns FDA Breakthrough Therapy Designation for Platinum-Resistant Ovarian Cancer

Lilly’s Sacituzumab Govitecan Receives U.S. FDA Breakthrough Therapy Designation for Platinum-Resistant Ovarian Cancer Eli Lilly and Company today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for the treatment of adult patients…

Read MoreLilly’s Mirvetuximab Soravtansine Earns FDA Breakthrough Therapy Designation for Platinum-Resistant Ovarian Cancer
Moderna

Moderna & Merck: 5-Year Data Show Sustained RFS Benefit with Intismeran + KEYTRUDA® in High-Risk Melanoma

Moderna and Merck Report Five-Year Data Showing Sustained Improvement in Recurrence-Free Survival with Intismeran Autogene Plus KEYTRUDA® in High-Risk Stage III/IV Melanoma Patients After Complete Resection Moderna, Inc. and Merck (NYSE: MRK), known as MSD outside of the United States and…

Read MoreModerna & Merck: 5-Year Data Show Sustained RFS Benefit with Intismeran + KEYTRUDA® in High-Risk Melanoma
Shionogi

Shionogi Wins Health Minister Award for Cefiderocol at Japan AMED Grand Prize

Shionogi Receives Minister of Health, Labour and Welfare Award for Cefiderocol at the 8th Japan Medical Research and Development Grand Prize Shionogi & Co., Ltd.  (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereinafter, “Shionogi”) announced that it had…

Read MoreShionogi Wins Health Minister Award for Cefiderocol at Japan AMED Grand Prize

Bayer Applauds U.S. Supreme Court’s Decision to Review Durnell Case in Roundup™ Litigation

Bayer Applauds U.S. Supreme Court’s Decision to Review Durnell Case in Roundup™ Litigation The U.S. Supreme Court today announced that it will review the Durnell Roundup™ case. Monsanto petitioned the court to hear Durnell in April 2025 and address the split in authority among…

Read MoreBayer Applauds U.S. Supreme Court’s Decision to Review Durnell Case in Roundup™ Litigation

Opdivo® + Yervoy® Approved in Taiwan for MSI-H/dMMR Metastatic Colorectal Cancer

Opdivo® IV Infusion Approved in Taiwan in Combination with Yervoy® for Adults with Unresectable or Metastatic MSI-H/dMMR Colorectal Cancer Ono Pharmaceutical Co., Ltd. today announced that Ono Pharma Taiwan Co., Ltd. (Taipei, Taiwan; “OPTW”), a Taiwanese subsidiary of Ono, received…

Read MoreOpdivo® + Yervoy® Approved in Taiwan for MSI-H/dMMR Metastatic Colorectal Cancer

Neurocrine Shows INGREZZA® Achieves Higher VMAT2 Occupancy Than AUSTEDO XR

Neurocrine Biosciences Presents Head-to-Head Data Showing INGREZZA® (valbenazine) Capsules Achieve Higher VMAT2 Target Occupancy Than AUSTEDO XR Neurocrine Biosciences, Inc. today announced the presentation of the first head-to-head data comparing vesicular monoamine transporter 2 (VMAT2) target occupancy between INGREZZA® (valbenazine) capsules and AUSTEDO XR…

Read MoreNeurocrine Shows INGREZZA® Achieves Higher VMAT2 Occupancy Than AUSTEDO XR

Bristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Teens with oHCM

BMS Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Teens with oHCM Bristol Myers Squibb today announced positive topline results from SCOUT-HCM, a Phase 3 trial evaluating Camzyos (mavacamten) in the first study of a cardiac myosin inhibitor (CMI) in adolescents…

Read MoreBristol Myers Squibb Reports Positive Phase 3 SCOUT-HCM Results for Camzyos in Teens with oHCM

Gordian Bio Announces Collaboration with Pfizer on Obesity In Vivo Target Research

Gordian Bio Enters Research Partnership with Pfizer to Drive Obesity Target Discovery Gordian Bio, a biotechnology company pioneering large-scale in vivo functional genomics to unlock validated drug targets for chronic diseases, today announced a non-exclusive research collaboration with Pfizer to…

Read MoreGordian Bio Announces Collaboration with Pfizer on Obesity In Vivo Target Research

Rick R. Suarez Appointed U.S. President and Head of the BioPharmaceuticals Business Unit

The appointment strengthens leadership of the company’s U.S. BioPharmaceuticals operations and strategic growth AstraZeneca has named Rick R. Suarez Senior Vice President, US President and Head of the US BioPharmaceuticals Business Unit.Suarez will lead the execution of the Company’s previously…

Read MoreRick R. Suarez Appointed U.S. President and Head of the BioPharmaceuticals Business Unit